# Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

Source: https://onco.cc/trials/nct04687241/  
OnCo record `nct04687241` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Aumolertinib in non-small-cell lung cancer and small-cell lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations is a phase 3 interventional study registered as NCT04687241 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 192 participants planned, started 2021-04-30 and due to reach its primary completion in 2024-07-08. Interventions recorded: Almonertinib, Placebo Almonertinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04687241
- Phase: 3
- Setting: Efficacy and Safety of Almonertinib Versus Placebo as Adjuvant Therapy for Subjects With Resected Stage II-IIIB NSCLC Harboring EGFR-sensitive Mutations: A Randomized, Controlled, Double-blind, Phase 3 and Multicenter Clinical Study
- Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Enrolled: 192

## Sources

- ClinicalTrials.gov NCT04687241: https://clinicaltrials.gov/study/NCT04687241

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Aumolertinib](https://onco.cc/drugs/aumolertinib/)

---
JSON: https://onco.cc/api/v1/entities/nct04687241.json